Rwanda to receive experimental vaccines to combat Marburg outbreak
Rwanda is facing a Marburg virus outbreak with 41 cases and 12 deaths. Experimental vaccines and therapeutics, including a U.S.-supplied vaccine and remdesivir, will undergo clinical trials soon.
Read original article
Rwanda is set to receive experimental vaccines and therapeutics to combat a significant outbreak of the Marburg virus, with clinical trials expected to commence shortly. The outbreak has already resulted in 41 cases, including 12 fatalities, primarily affecting healthcare workers in Kigali. The U.S. government is supplying doses of a single-dose vaccine developed by the Sabin Vaccine Institute, along with Gilead Sciences' antiviral drug remdesivir and Mapp Biopharmaceutical's monoclonal antibody MBP-091. Rwanda's Health Minister, Sabin Nsanzimana, emphasized the urgency of the situation, stating that the trials aim to protect healthcare providers. The Sabin vaccine is currently in a Phase 2 trial in Uganda and Kenya, and its rapid deployment in Rwanda is facilitated by prior preparatory work by the World Health Organization and other partners. The collaboration between the Rwandan government and health organizations has been crucial in enabling a swift response to the outbreak, which was first confirmed recently.
- Rwanda is experiencing a significant Marburg virus outbreak with 41 cases reported.
- Experimental vaccines and therapeutics are being deployed for clinical trials.
- The U.S. government is providing vaccines and therapeutics, including remdesivir.
- The Sabin Vaccine Institute's vaccine is the most advanced in development.
- Rapid response efforts are supported by the Rwandan government's health infrastructure.
Related
New HIV Prevention Drug Shows 100% Efficacy in Clinical Trial
A new HIV prevention drug, lenacapavir, has shown 100% efficacy in a trial in South Africa and Uganda for young women. It outperformed daily pills like Truvada and Descovy, offering hope for improved prevention methods.
Twice-yearly injection offers 100% protection against HIV
A study found lenacapavir injections provide 100% protection against HIV in young women and girls. Conducted in South Africa and Uganda, it highlights potential advancements in HIV prevention and affordability concerns.
WHO Declares Global Emergency over New Mpox Outbreak
The W.H.O. declared a global health emergency for mpox, primarily affecting the DRC with over 14,000 cases. Vaccination efforts are limited, and international cooperation is crucial to control the outbreak.
WHO Declares Mpox Global Health Emergency
The WHO declared the mpox outbreak in Africa a public health emergency, with over 450 deaths in the Democratic Republic of Congo and concerns over the new Clade 1b variant.
WHO declares mpox outbreak a public health emergency of international concern
The WHO has declared the mpox outbreak in the DRC a public health emergency, citing rapid spread and a new clade, while seeking $15 million for response efforts and vaccine access.
1 commentsRelated
New HIV Prevention Drug Shows 100% Efficacy in Clinical Trial
A new HIV prevention drug, lenacapavir, has shown 100% efficacy in a trial in South Africa and Uganda for young women. It outperformed daily pills like Truvada and Descovy, offering hope for improved prevention methods.
Twice-yearly injection offers 100% protection against HIV
A study found lenacapavir injections provide 100% protection against HIV in young women and girls. Conducted in South Africa and Uganda, it highlights potential advancements in HIV prevention and affordability concerns.
WHO Declares Global Emergency over New Mpox Outbreak
The W.H.O. declared a global health emergency for mpox, primarily affecting the DRC with over 14,000 cases. Vaccination efforts are limited, and international cooperation is crucial to control the outbreak.
WHO Declares Mpox Global Health Emergency
The WHO declared the mpox outbreak in Africa a public health emergency, with over 450 deaths in the Democratic Republic of Congo and concerns over the new Clade 1b variant.
WHO declares mpox outbreak a public health emergency of international concern
The WHO has declared the mpox outbreak in the DRC a public health emergency, citing rapid spread and a new clade, while seeking $15 million for response efforts and vaccine access.